Clinical response and side effects of metoclopramide: Associations with clinical, demographic, and pharmacogenetic parameters

Journal of Clinical Gastroenterology

Volumn 46, Issue 6, 2012, Pages 494-503

  Parkman, Henry P ^a   Mishra, Anurag ^a,b   Jacobs, Michael ^a   Pathikonda, Murali ^a   Sachdeva, Priyanka ^a   Gaughan, John ^b   Krynetskiy, Evgeny ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

gastroparesis; metoclopramide; pharmacogenomics; Reglan

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; METOCLOPRAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; SEROTONIN 4 RECEPTOR;

ADULT; AGE; ANXIETY; BODY MASS; CONFUSION; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DIABETIC PATIENT; DNA ISOLATION; DYSTONIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUSCLE TWITCH; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEIZURE; SEX; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH EMPTYING; STOMACH PARESIS; TARDIVE DYSKINESIA; TREMOR; WEIGHT;

ADULT; AGE FACTORS; BODY MASS INDEX; DIABETES MELLITUS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC EMPTYING; GASTROPARESIS; GENOTYPE; HUMANS; MALE; METOCLOPRAMIDE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84862274427     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182522624     Document Type: Review

References (36)

1. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association medical position statement: Diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1589-1591.
2. Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med. 2007;356:820-829.
3. Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: A multidisciplinary clinical review. Neurogastroenterol Motil. 2006;18:263-283.
4. Ahmad N, Keith-Ferris J, Gooden E, et al. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol. 2006;6:571-576.
5. Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: Astablishment of international control values. Am J Gastroenterol. 2000;95:1456-1462.
6. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: A joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol. 2008;103:753-763.
7. Maranki JL, Lytes V, Meilahn JE, et al. Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis. Dig Dis Sci. 2008;53:2072-2078.
8. Parkman HP, Jacobs MR, Mishra A, et al. Domperidone treatment for gastroparesis: Demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci. 2011;56:115-124.
9. Liu K, Muse SV. PowerMarker: An integrated analysis environment for genetic marker analysis. Bioinformatics. 2005;21:2128-2129.
10. Desta Z, Wu GM, Morocho AM, et al. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos. 2002;30:336-343.
11. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit. 2004;26:180-185.
12. Bakker PR, Van Harten PN, Van OJ. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: A meta-Analysis. Schizophr Res. 2006;83:185-192.
13. Sissung TM, Baum CE, Kirkland CT, et al. Pharmacogenetics of membrane transporters: An update on current approaches. Mol Biotechnol. 2010;44:152-167.
14. Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Avaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos. 2005;33:165-174.
15. Jolliet P, Nion S, Allain-Veyrac G, et al. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacol Res. 2007;56:11-17.
16. Gralla RJ. Metoclopramide. A review of antiemetic trials. Drugs. 1983;25(suppl 1):63-73.
17. Dan Y, Murakami H, Koyabu N, et al. Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil. J Pharm Pharmacol. 2002;54:729-733.
18. Eneroth A, Astrom E, Hoogstraate J, et al. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur J Pharm Sci. 2001;12:205-214.
19. Muller DJ, Shinkai T, De L, et al. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J. 2004;4:77-87.
20. Van Der Padt A, Van Schaik RH, Sonneveld P. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. Neth J Med. 2006;64:160-162.
21. Rao AS, Camilleri M. Review article: Metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11-19.
22. Straus SM, Sturkenboom MC, Bleumink GS, et al. Noncardiac Qtc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26:2007-2012.
23. Farrelly AM, Ro S, Callaghan BP, et al. Expression and function of KCNH2 (HERG) in the human jejunum. Am J Physiol Gastrointest Liver Physiol. 2003;284:G883-G895.
24. Shoeb F, Malykhina AP, Akbarali HI. Cloning and functional characterization of the smooth muscle ether-A-go-go-related gene K+ channel. Potential role of a conserved amino acid substitution in the S4 region. J Biol Chem. 2003;278: 2503-2514.
25. Medhurst AD, Lezoualc'h F, Fischmeister R, et al. Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT-PCR. Brain Res Mol Brain Res. 2001;90:125-134.
26. Dumuis A, Sebben M, Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists at the nonclassical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol. 1989;340:403-410.
27. Guillemot J, Compagnon P, Cartier D, et al. Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocr Relat Cancer. 2009;16: 281-290.
28. Ohtsuki T, Ishiguro H, Tera-Wadleigh SD, et al. Association between serotonin 4 receptor gene polymorphisms and bipolar disorder in Japanese case-control samples and the NIMH genetics initiative bipolar pedigrees. Mol Psychiatry. 2002; 7:954-961.
29. Suzuki T, Iwata N, Kitamura Y, et al. Association of a haplotype in the serotonin 5-HT4 receptor gene (HTR4) with Japanese schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2003;121B:7-13.
30. Manabe N, Wong BS, Camilleri M. New-generation 5-HT4 receptor agonists: Potential for treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2010;19: 765-775.
31. Clark DA, Arranz MJ, Mata I, et al. Polymorphisms in the promoter region of the alpha1A-Adrenoceptor gene are associated with schizophrenia/ schizoaffective disorder in a Spanish isolate population. Biol Psychiatry. 2005;58:435-439.
32. Nonen S, Okamoto H, Fujio Y, et al. Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1D are associated with the response to beta-blockers in dilated cardiomyopathy. Pharmacogenomics J. 2008;8:78-84.
33. Manly KF. Reliability of statistical associations between genes and disease. Immunogenetics. 2005;57:549-558.
34. Hirschhorn JN, Lohmueller K, Byrne E, et al. A comprehensive review of genetic association studies. Genet Med. 2002;4:45-61.
35. Sullivan PF. Spurious genetic associations. Biol Psychiatry. 2007;61:1121-1126.
36. Lewis CM. Genetic association studies: Design, analysis and interpretation. Brief Bioinform. 2002;3:146-153.